Strong relationships between disease activity, foot-related impairments, activity limitations and participation restrictions in children with juvenile idiopathic arthritis.
Menno Dekker(Center for Rheumatology), Leo D. Roorda(Academic Center for Dentistry Amsterdam), Heleen Beckerman(Amsterdam Neuroscience), Agnes F. Hoeksma(Reade), Jos H. M. Dekker, Marion A. J. van Rossum(Reade), Koert M. Dolman(Reade)
PubMed
March 18, 2011
Cited by 15
Related Papers
Anakinra as first‐line disease‐modifying therapy in systemic juvenile idiopathic arthritis: Report of forty‐six patients from an international multicenter series
|Arthritis & Rheumatism|2010|465
Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register
|Annals of the Rheumatic Diseases|2008|220
Sulfasalazine in the treatment of juvenile chronic arthritis: A randomized, double-blind, placebo-controlled, multicenter study
|Arthritis & Rheumatism|1998|217
Predictors of health‐related quality of life in children and adolescents with juvenile idiopathic arthritis: Results from a web‐based survey
|Arthritis Care & Research|2012|155